Last updated: 11/07/2018 09:31:27
Bupropion & Cardio Birth Defect (Slone)
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Bupropion and Cardiac Birth Defects (Slone Epidemiology Center)
Trial description: Bupropion is a unique drug that is used both to treat depression and as an aid in smoking cessation. In 2008, the final report from the Bupropion pregnancy registry described 24 congenital malformations among the 675 women exposed to bupropion in the first trimester of pregnancy. Of these, 9 had congenital heart disease of varying severity, including a number of infants with ventricular septal defects (VSDs); of note, 2 of these 9 had coarctation of the aorta. More recently, Alwan et al, in an analysis of data from the Centers for Disease Control and Prevention’s case-control National Birth Defects Prevention Study, reported an increased risk of left outflow tract heart defects, a subgroup of cardiac malformations that includes coarctation of the aorta and hypoplastic left heart syndrome. Data from the Slone Epidemiology Center Birth Defects Study will be used to test these observations. The outcomes of primary interest will include those hypothesized to be associated with bupropion in recent studies: left outflow tract defects considered as a group. Coarctation of the aorta and hypoplastic left heart syndrome will also be examined separately. All infants with congenital heart defects are further classified into subgroups that are embryologically meaningful, including left outflow tract defects. In secondary analyses, other heart defect classes for which there are adequate numbers of cases will be evaluated.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Diagnosis of left outflow tract defects
Timeframe: Within 6 months of delivery
Diagnosis of coarctation of the aorta
Timeframe: Within 6 months of delivery
Diagnosis of hypoplastic left heart syndrome
Timeframe: Within 6 months of delivery
Secondary outcomes:
Diagnosis of other congenital heart defects
Timeframe: Within 6 months of delivery
Interventions:
Enrollment:
1
Primary completion date:
Not applicable
Observational study model:
Case-Control
Time perspective:
Retrospective
Clinical publications:
Louik C, Kerr S, Mitchell AA.First-Trimester Exposure to Bupropion and Risk of Cardiac Malformations.Pharmacoepidemiol Drug Saf.2014;23(10):1066-1075
- Subjects with congenital heart defects who are born within the catchment areas of the 4 study centers
- A sample of nonmalformed infants born at participating hospitals
- Infants with chromosomal anomalies
Inclusion and exclusion criteria
Inclusion criteria:
- Subjects with congenital heart defects who are born within the catchment areas of the 4 study centers
- A sample of nonmalformed infants born at participating hospitals
- Subjects who were interviewed in 1992 or later
- Women who complete the study interview within 6 months of the infant’s birth
Exclusion criteria:
- Infants with chromosomal anomalies
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2012-10-08
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website